(NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology ... from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process on the overall design ...

(NASDAQ: RNAC) (the“Company”), a clinical-stage biotechnology ... from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process on the overall design ...

(NASDAQ: RNAC) (the "Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has received written agreement from the U.S. Food ...

(NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has received written agreement from the U.S. Food ...

The FDA has published its long-awaited update to guidance to make sure clinical trials more closely reflect the range of patients that might be treated with a new therapy in the real world.

Two days into the Trump administration, several webpages covering diversity in clinical trials, annual medical device reports and LGBTQ+ information were removed from the Food and Drug ...

Some of the removed FDA pages related to efforts around diversity, gender and health equity. “Surely there’s someone who’s knowledgeable enough about science to understand the importance of diversity ...

Despite more treatment options being a positive, Ben Hargreaves finds that this has raised issues over single-region clinical trials, leading to the FDA rejecting certain treatments and clarifying ...

US FDA Drops Web Pages on Improving Clinical Trial Diversity By Julie Steenhuysen CHICAGO (Reuters) - The U.S. Food and Drug Administration has pulled draft guidance from its website requiring ...